INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 145 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2021. The put-call ratio across all filers is 1.70 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $504,000 | -22.5% | 36,200 | -23.1% | 0.00% | -33.3% |
| Q2 2022 | $650,000 | +44.4% | 47,100 | +70.0% | 0.00% | +50.0% |
| Q1 2022 | $450,000 | -45.9% | 27,700 | -45.8% | 0.00% | -33.3% |
| Q4 2021 | $832,000 | +9.8% | 51,100 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $758,000 | +143.7% | 51,100 | +227.6% | 0.00% | +200.0% |
| Q2 2021 | $311,000 | +498.1% | 15,600 | +1318.2% | 0.00% | – |
| Q2 2020 | $52,000 | +766.7% | 1,100 | +1000.0% | 0.00% | – |
| Q1 2020 | $6,000 | -97.6% | 100 | -95.0% | 0.00% | -100.0% |
| Q4 2019 | $247,000 | +177.5% | 2,000 | +150.0% | 0.00% | – |
| Q1 2019 | $89,000 | -32.1% | 800 | -38.5% | 0.00% | -100.0% |
| Q4 2018 | $131,000 | +4.0% | 1,300 | +30.0% | 0.00% | 0.0% |
| Q3 2018 | $126,000 | -98.0% | 1,000 | -97.5% | 0.00% | -96.3% |
| Q4 2014 | $6,240,000 | +2263.6% | 40,000 | +4900.0% | 0.03% | +2600.0% |
| Q1 2014 | $264,000 | +58.1% | 800 | -67.0% | 0.00% | 0.0% |
| Q3 2013 | $167,000 | +53.2% | 2,422 | 0.0% | 0.00% | – |
| Q2 2013 | $109,000 | – | 2,422 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $9,514,000 | 1.49% |
| CM Management, LLC | 45,000 | $668,000 | 0.50% |
| EULAV Asset Management | 660,000 | $9,801,000 | 0.26% |
| DLD Asset Management, LP | 225,200 | $3,346,000 | 0.24% |
| Virtus ETF Advisers LLC | 21,387 | $318,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 79,145 | $1,175,000 | 0.12% |
| Hennion & Walsh Asset Management, Inc. | 136,720 | $2,030,000 | 0.11% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $2,507,000 | 0.08% |
| Inspire Investing, LLC | 31,868 | $473,000 | 0.06% |
| DUALITY ADVISERS, LP | 51,196 | $760,000 | 0.06% |